McKesson and Oracle are among the final bidders vying to acquire EMR data company Veradigm (OTC: MDRX), sources tell Axios.
Why it matters: Veradigm, née Allscripts, is likely to command a valuation above its $1 billion market cap, they say, citing lower risk of antitrust scrutiny in the incoming administration.
